We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Effects of Huangqin Qingre Chubi Capsule on PPAR-γ/CD36/MnSOD axis and oxidative stress immune inflammation in patients with rheumatoid arthritis.
- Authors
GUO Jinchen; LIU Jian; ZHANG Xiaojiin; ZHOU Qiao; HUANG Dan
- Abstract
Objective To study the effects of Huangqin Qingre Chubi (Scutellaria Heat-clearing Impediment-eliminating, HQC) Capsule on oxidative stress immune inflammation in patients with Rheumatoid Arthritis (RA) by regulating Peroxisome Proliferator-activated Receptor-γ (PPAR-γ)/CD36/Manganese Superoxide Dismutase (MnSOD) axis, and to explore its anti-oxidation, anti-inflammatory and anti-immune mechanism. Methods 60 RA patients hospitalized in Department of Rheumatology, the First Affiliated Hospital of Anhui University of Chinese Medicine from December 2018 to December 2020 were randomly divided into control group and experimental group (n =30 in each group). The control group received conventional anti-symptomatic treatment alone, while the experimental group was additionally treated with HQC Capsule. The course of treatment was 8 weeks. The joint and systemic symptoms of RA patients before and after treatment were evaluated. Laboratory parameters such as Erythrocyte Sedimentation Rate (ESR), Rheumatoid Factor (RF), Anti-cyclic Citrullinated Peptide Antibody (CCP-AG) and C-reactive Protein (CRP) were measured. Serum levels of Tumor Necrosis Factor-α (TNF-α), Interleukin-10 (IL-10), Lipid Peroxide (LPO), Malondialdehyde (MDA), Superoxide Dismutase (SOD) and Total Antioxidant Capacity (TAOC) were detected by using ELI ISA. The level of CD36 in monocytes was measured with FCM. The expression of PPAR-γ and MnSOD protein was detected by using Western blot assay. Results The total effective rates of experimental group and control group were 90.0% and 83. 3% respectively, and the clinical efficacy of experimental group was better than that of control group (P < 0.05). Compared with those before treatment, the scores of systemic symptoms of the experimental group M1 decreased significantly (P < 0.05 or P < 0.01). After treatment, the experimental group performed better in the improvement of morning joint stiffness, reduced appetite, lack of qi, no desire to speak, joint heaviness and abdominal distension after eating and loose stools (P < 0.05 or P < 0.01). RF, CRP, ESR, TNF-α and MDA in the two groups both decreased significantly after treatment while the expressions of IL-10, CD36, PPAR-γ and MnSOD increased significantly; and the expressions of SOD and TAOC in the experimental group increased while LPO decreased significantly (P < 0.05 or P < 0.01). After treatment, the experimental group also had a better outcome than control group in reducing ESR and increasing the expressions of IL-10, SOD, CD36, PPAR-γ and MnSOD (P < 0.05 or P < 0.01). Conclusion HQC may regulate oxidative stress and inflammatory immune response, and improve the clinical symptoms of RA via regulating PPAR-γ/CD36/MnSOD axis.
- Publication
Journal of Beijing University of Traditional Chinese Medicine, 2022, Issue 2, p201
- ISSN
1006-2157
- Publication type
Academic Journal
- DOI
10.3969/j.issn.1006-2157.2022.02.015